Italia markets closed

AstraZeneca PLC (AZN)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
55,21+0,16 (+0,29%)
Alla chiusura: 4:00PM EDT
Accedi per pubblicare un messaggio.
  • B
    BioTech20yrs
    $PFE conversation
    $AZN EU Ditches AstraZeneca Vaccine. It's Pivoting to Pfizer. --
  • t
    the_entitled
    $PFE made its $ so it’s voting yes. $MRNA got gov money so it’s a coercive yes. $JNJ $AZN didn’t work anyway so they could vote yes. $NVAX is the one that looses the most. 3 decades of research going to the drain.
  • M
    Michael1
    $NVAX conversation
    $MRNA and $BNTX are getting crushed pre market, likely due to the freshly released Oxford study. Taking us down with them it looks like - same trendlines. Big Pharma is spinning it that you are 10x more likely to get a blood clot from COVID than the vaccine, but they aren't looking solely at the female cohort, which appears to be most affected here. $AZN & $JNJ are going to come back online, and our SP will suffer as a result. Only 1 million shares left to short according to iborrowdesk.
    https://www.cbsnews.com/news/covid-vaccine-blood-clots-study-pfizer-astrazeneca-moderna-oxford/
  • A
    Anonymous
    $HGEN conversation
    This was a huge steal from $AZN and screams positive for either future success or a buyout. Company is setting up its long game to take it there if it needs to, but also driving up the price if the they want to cash out big quickly. Personally hope for the latter

    https://finance.yahoo.com/news/humanigen-appoints-dr-adrian-kilcoyne-110000331.html
    Humanigen announced the appointment of Adrian Kilcoyne, MD, MBA, MPH, to the newly-created role of Chief Medical Officer.
    Humanigen announced the appointment of Adrian Kilcoyne, MD, MBA, MPH, to the newly-created role of Chief Medical Officer.
    finance.yahoo.com
  • B
    BioTech20yrs
    $AZN conversation
    $AZN
    EU Ditches AstraZeneca Vaccine. It's Pivoting to Pfizer.
  • M
    Michael1
    $NVAX conversation
  • T
    Tim
    $VXRT conversation
    $JNJ needs to decide on $VXRT in Q2...perhaps this leaked.. also $AZN s failures will help the probability of Vaxart getting gov't funding and being included in the EUA. Most other countries still desperately need vaccines and an easy way to distribute so even if the US doesn't fund i'd be amazed if another country didn't step in soon...
  • R
    Russ
    $JNJ happy to sell anticoagulants along $AZN vaccine. That’s the advantage of being approved last like $NVAX you make sure there’s no blood clots side effects. Europe will drop AZN to get NVAX instead...$500 a cometh.
  • K
    Kevin
    $AZN Will go to $80 this week the bears trying to short it have no chance
  • S
    ScorpionLeather
    $GALT conversation
    $GALT $AZN New study by AstraZeneca and Swedish researchers finds that Galectin-3 expression is central to myocardial infarction (heart attack).

    It follows, there may be very large potential for the use of a galectin-3 inhibitor for heart attack prevention and recovery. This adds to other evidence in published papers regarding the role of gal3 in MI.

    According to the paper,

    "Lgals3 (encodes galectin-3) and Prkaca were among the most central genes in central clusters (Table S6)."

    "Lgals3, related to acute inflammation response, has been studied intensively in recent years as a key gene in CVD, and as a potential CVD therapy target (Suthahar et al., 2018; Zhong et al., 2019)."

    Revealing tissue-specific metabolic crosstalk after a myocardial infarction

    https://www.biorxiv.org/content/10.1101/2020.10.28.358556v1
    Myocardial infarction (MI) promotes a range of systemic effects, many of which are unknown. Here, we investigated the alterations associated with MI progression in heart and other metabolically active tissues (liver, skeletal muscle, and adipose) in
    Myocardial infarction (MI) promotes a range of systemic effects, many of which are unknown. Here, we investigated the alterations associated with MI progression in heart and other metabolically active tissues (liver, skeletal muscle, and adipose) in
    www.biorxiv.org
  • T
    Tsering
    Novavax, Inc.
    $jnj paused ! $azn useless, guess which one is gonna save the world . its novavax . $nvax
  • Z
    Zohaib
    So strange or scandle..??
    Many stock if we have positive news stock never rise straight way they take days and when we have bad news straightaway they go down even 70 80% even market is closed... $Azn.l clearly banned many countries their vaccines 💉 and still growing how is it possible?? ❌❌❌❌
  • T
    Tim
    $AZN conversation
    New $AZN Kidney Disease drug showing stellar progress in phase iii trials

    https://www.biospace.com/article/astrazeneca-s-farxiga-hits-the-mark-in-chronic-kidney-disease
    AstraZeneca reported successful results from its Phase III DAPA-CKD clinical trial of Farxiga (dapagliflozin) in end stage kidney disease (ESKD).
    AstraZeneca reported successful results from its Phase III DAPA-CKD clinical trial of Farxiga (dapagliflozin) in end stage kidney disease (ESKD).
    www.biospace.com
  • e
    elisworld
    $AZN conversation
    Earlier CNBC TV mentioned that #AZN mentioned the vaccine may provide protection for 1+ years. Something that no other company has dared to say! This will work out very well for the company. This is one of the safest vaccines to date, they have good production capacity (which other companies do not have), and the vaccine is expected to have good double layer protection (antibody and T-cell). I think this is just short term profit taking and expect in another week or so this will be over $65.
  • U
    Uncle
    $INO conversation
    After spending the past 8 years scripting a turnaround that would make AstraZeneca $AZN a reliable growth story and global performer in oncology, CEO Pascal Soriot has bought out Alexion $ALXN, a mid-sized biotech that helped make rare diseases trendy.

    [Ino is also a player in oncology VGX-3100, head-neck cancer w/AZN, and rare orphan diseases in RRP Ino-4701, AIN/VIN VGX-3100, GBM Ino-5401.]

    Investors at Alexion are getting $175 a share — $60 in cash and the rest in company stock — making this a $39 billion buyout. That qualifies as the biggest M&A deal of 2020 in biopharma, a year in which easy bolt-ons have dominated.

    This bigger buyout may not be quite so easy. But it’s lining up as another numbers deal, designed to boost revenue dependably without adding much in the way of pipeline risk.

    The new cash flow will boost AstraZeneca’s revenue, once the deal is wrapped around Q3 next year, putting their investors in line for a bigger dividend. That will gain some applause, without stirring much broader excitement.

    Soriot isn’t just buying a new Boston-based biotech wing to add revenue, though. He says he now intends to plant the AstraZeneca flag in front of a rare disease pipeline focused on immunology — with the clear intention of adding to that string.

    The CEO also offered a tip of the hat to a frequently discounted pipeline: “Factor D small-molecule inhibitors of the alternative pathway of the complement system, an antibody blocking neonatal Fc receptor (FcRn)-mediated recycling, and a bi-specific mini-body targeting C5, among others. The FcRn extends the half-life and hence the availability of pathogenic immunoglobulin G (IgG) antibodies.”

    Perhaps, or perhaps that’s what is expected in a big bolt-on of this kind, which tacks on franchise revenue rather than transforms the company. In that sense it looks a lot like the Allergan buyout by AbbVie, which won over analysts to the notion that the buyer could enhance revenue. Tim Anderson at Wolfe — a big fan of the turnaround executed by Soriot and his team ahead of this deal — highlights the AstraZeneca pitch, promising to do better with Alexion revenue than Alexion would have.

    That’s a credible strategy for making the numbers work with investors and the rest of the analyst corps.

    As SVB Leerink analyst Geoffrey Porges noted Saturday morning, Alexion’s stock has floundered for years — which is one reason why it’s still attractive to AstraZeneca in an industry where prize companies win extraordinary valuations. That weak overall stock performance brought in the activists at Elliott this year — who demanded that Hantson find a buyout just like this — and created considerable discontent among the stockholders.

    Rivals, meanwhile, have been pursuing Alexion’s C5 franchise with new drugs that threaten the biotech’s preeminence in the C5 space. And AstraZeneca itself has faced probing questions recently over the way it handled the data from its pivotal study of their Covid-19 vaccine, which looms as ever more important as the Sanofi/GSK team are forced to regroup after their first foray in the clinic ended in failure.

    Also, not all of the investors may be instantly ready to hand over the company for $175.

    With Alexion tucked into AstraZeneca’s global ops, Porges sees the company as more valuable than the $175 per share on the table. He wants to see $200. Porges noted:

    Alexion’s franchise is far more valuable in the hands of a large diversified company than it is independently, in our view. A diversified company will enjoy the valuation premium of diversification, compared to the discount (25-35%) carried by Alexion’s stock based on its concentration, and a diversified company will be able to eliminate much of the overhead associated with the global operations of a mid-sized biopharma company. Finally, over the long term, rare diseases are one of the most attractive business segments in biopharma, and most large diversified companies are invested, or investing, in this category.
    Provided the deal goes through, the next step usually involves clearing the deck of an weak players in the pipeline, finding any synergies on the table and then going back in with new deals. Soriot, however, turned into a very selective buyer after he had been at AstraZeneca for a few years. The first few years of his tenure had been centered on a flurry of deals, many of which didn’t pan out, after being handed one of the weakest pipelines in the global business. So we’ll be watching closely to see what gets his attention.
  • S
    ScorpionLeather
    $GALT conversation
    $GALT $AZN New study by AstraZeneca and Swedish researchers finds that Galectin-3 expression is central to myocardial infarction (heart attack).

    It follows, there may be very large potential for the use of a galectin-3 inhibitor for heart attack prevention and recovery. This adds to other evidence in published papers regarding the role of gal3 in MI.
    According to the paper,

    "Lgals3 (encodes galectin-3) and Prkaca were among the most central genes in central clusters
    378 (Table S6)."

    "Lgals3, related to acute inflammation response, has been studied intensively in recent years as a key gene in CVD, and as a potential CVD therapy target (Suthahar et al., 2018; Zhong et al., 2019)."

    Revealing tissue-specific metabolic crosstalk after a myocardial infarction

    https://www.biorxiv.org/content/10.1101/2020.10.28.358556v1
    Myocardial infarction (MI) promotes a range of systemic effects, many of which are unknown. Here, we investigated the alterations associated with MI progression in heart and other metabolically active tissues (liver, skeletal muscle, and adipose) in
    Myocardial infarction (MI) promotes a range of systemic effects, many of which are unknown. Here, we investigated the alterations associated with MI progression in heart and other metabolically active tissues (liver, skeletal muscle, and adipose) in
    www.biorxiv.org
  • F
    FringDook
    $CGEN conversation
    Little bit of positive PR to lubricate the engine, let's get this party started. Only 2 million in royalties associated with one of their contracts with $AZN $CGEN however it is always nice to have organic revenues and with up to 200 million in additional payment if the trials are a success
  • N
    Neil
    $NVAX conversation
    2/7/21 CV19 Latest Efficacy Variants%:
    [Overall%,🇨🇳prim%,🇬🇧var%,🇿🇦var%,🇧🇷var%]

    1. $NVAX [$19B]: [89%,96%,86%,60%,NA]
    2. $AZN [$130B]: [82%,NA,NA,no bueno,NA]
    3. $MRNA [$70B]: [NA,95%,NA,NA,NA]
    4. $BNTX [$28B]: [NA,95%,NA,NA,NA]
    5. $JNJ [$432B]: [66%,72%,NA,57%,NA]
    6. $CVAC [$22B]: [NA,NA,NA,NA,NA]
    7. $INO [$2.2B]: [NA,NA,NA,NA,NA]
    8. $VXRT [$0.8B]: [NA,NA,NA,NA,NA]

    ---------------
    AZN & JNJ 1st solutions are in trouble. They need quick turnaround with next versions to handle primary & 3+ variants.
    ---------------
    Since multiple variants are identified, the race is wide open again for the small horses to catch up.
    ---------------
    CV19 terminologies:
    1. Sars-CoV2 -- 🇨🇳primary
    2. B117-- 🇬🇧variant
    3. B1351 -- 🇿🇦variant
    4. P1 -- 🇧🇷variant
    ---------------
    Notes:
    +These are rough numbers provided by vaccine makers. Check their PRs.
    +JNJ vaccine is single shot 💉.
    +VXRT vaccine comes in pill 💊 form.
    +INO vaccine is DNA platform.
    +NVAX 🇿🇦variant% is for HIV-.
  • e
    elisworld
    $AZN conversation
    Bought a big chunk of shares today, I know I am a little late to the party, but I don't think I'm too late since we still have yet to see trial results. Good luck to everyone Monday! My prediction is the results will be solid (due to the strong academic work of Oxford Vaccine Group and Oxford University) and the stock will open at $65 and move higher through the day. #AZN could move into the #1 global vaccine supplier with good results. Up another 1% after hours.
  • e
    elisworld
    $AZN conversation
    Analyst from Jeffries is coming to #AZN 's defence:
    "AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies"

    Read more at:
    https://thefly.com/landingPageNews.php?id=3128290
    AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies Jefferies AZN BNTX PFE MRNA
    AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies Jefferies AZN BNTX PFE MRNA
    thefly.com